Curaleaf Files to Acquire Aurora Cannabis for $272 Million

Deal Structure and Valuation Metrics

Curaleaf will issue 0.1127 subordinate voting shares for each Aurora common share, valuing Aurora at CAD $1.43 per share based on Curaleaf's August 14 closing price. The transaction represents a 22% premium to Aurora's 30-day volume-weighted average price. Aurora shareholders will own approximately 11% of the combined company post-close.

According to the merger agreement filed with the SEC, Curaleaf has structured the acquisition to avoid triggering Canadian takeover bid rules by keeping the exchange ratio below the 20% threshold that would require a formal tender offer under National Instrument 62-104. Two-thirds of Aurora shareholders must approve. So must regulators under the Investment Canada Act.

Cross-Border Tax Implications Under IRC §280E

The acquisition doesn't immediately resolve Curaleaf's §280E exposure on U.S. operations, but Aurora's Canadian licensed producer status may enable the combined entity to shift certain R&D and IP-holding functions to non-plant-touching subsidiaries. Under current IRS guidance, expenses incurred by a Canadian LP for activities not directly involving U.S. Schedule I substances remain deductible.

Curaleaf disclosed in its Q2 2026 10-Q that it paid an effective federal tax rate of 68% on U.S. operations due to §280E disallowances. Aurora, operating under Health Canada's Cannabis Act framework, has historically deducted cost of goods sold and SG&A expenses without restriction. The merger doesn't change the plant-touching classification of Curaleaf's U.S. retail and cultivation assets.

Regulatory Pathway and Timeline

The companies expect to close the transaction in Q4 2026, contingent on Hart-Scott-Rodino clearance in the U.S. and Competition Bureau approval in Canada. Neither jurisdiction has published formal guidance on cross-border cannabis M&A since the DEA's August 2024 notice of proposed rulemaking to reschedule cannabis to Schedule III.

Curaleaf CEO Boris Jordan stated in the August 15 press release that the deal "positions us to capture synergies across medical and adult-use channels as federal reform advances." Aurora didn't provide a standalone statement. If Aurora shareholders reject the deal or if a superior proposal emerges, Aurora owes a $15 million termination fee.

Combined Entity Financials and Market Position

Pro forma revenue for the combined company is projected at $1.87 billion for fiscal 2026, based on Curaleaf's $1.52 billion trailing twelve-month revenue and Aurora's CAD $312 million run rate. Curaleaf operates 156 dispensaries across 18 U.S. states. Aurora holds cultivation and processing licenses in eight countries but has scaled back international operations since 2023.

Annual cost synergies should hit $45 million by fiscal 2028, primarily from consolidating back-office functions and eliminating duplicate executive roles. Curaleaf's August 15 investor presentation didn't specify headcount reductions. Aurora's Edmonton headquarters will remain operational as a cultivation hub.

Canopy Growth Takeover Speculation

Canopy Growth Corp., which reported a net loss of CAD $1.2 billion in fiscal 2025, is widely viewed as the next consolidation candidate following the Curaleaf-Aurora announcement. Canopy's market capitalization of approximately CAD $890 million as of August 15, 2026 makes it an accessible target for U.S. MSOs with access to capital markets.

According to Canopy's most recent 10-K filed with the SEC, the company holds $267 million in cash and equivalents but carries $1.1 billion in long-term debt, including a $150 million convertible note due in June 2027. Any acquirer would need to address that maturity or negotiate a debt-for-equity conversion with noteholders.

Precedent Transactions and Valuation Benchmarks

The Curaleaf-Aurora deal is the first announced cross-border acquisition between a U.S. MSO and a Canadian LP since Trulieve's $2.1 billion purchase of Harvest Health & Recreation in 2021. That transaction, completed under Schedule I restrictions, required Trulieve to divest overlapping state licenses in Arizona and Florida to satisfy antitrust conditions.

Comparable M&A multiples for distressed Canadian LPs have ranged from 0.4x to 0.7x trailing revenue. Curaleaf is paying approximately 0.87x Aurora's fiscal 2026 revenue. That's a premium. It's justified by Aurora's EU GMP certification and its medical cannabis distribution agreements in Germany and Australia.

What Operators and Investors Should Watch

The key variable is whether the DEA finalizes Schedule III rescheduling before the Curaleaf-Aurora deal closes, which would materially alter the tax and banking profile of the combined entity. If rescheduling occurs, Curaleaf's U.S. operations would become eligible for full COGS and expense deductions under IRC §162, potentially reducing its effective tax rate from 68% to approximately 28%.

For full background on this story, see the CannIntel topic hub on the Curaleaf-Aurora acquisition. Next signal: shareholder vote scheduled for October 2026, with proxy materials expected by mid-September.